Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398908 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL119530 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29400620 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30291728 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL120255 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29867802 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1044856 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7420121 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29382791 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1000115 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| CN-1209361-C | Hydantoin-containing glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-07-06 | — | — | CN | disclosed |
| CN-1427838-A | Hydantoin-containing glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-07-02 | — | — | CN | disclosed |
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | TLR2 2904/4885MDM4 2629/4885TP53 2648/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885MDM4 441/4885TP53 34/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TLR2 3794/4885MDM4 1740/4885TP53 1257/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | TLR2 4837/4885MDM4 1200/4885TP53 88/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | TLR2 4611/4885MDM4 1294/4885TP53 178/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TLR2 2661/4885MDM4 1741/4885TP53 368/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | TLR2 3821/4885MDM4 441/4885TP53 34/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | TLR2 4097/4885MDM4 2155/4885TP53 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.